--- title: Buy Generic Harvoni Ledipasvir/Saofosbuvir Pills Online description: Harvoni combines Ledipasvir and Saofosbuvir for effective hepatitis C treatment. Order 90/400mg pills from our secure online pharmacy for reliable therapy. type: product language: en url: https://liabilis.com/order-harvoni-online-en.html availability: in_stock shipping: - type: Standard Airmail price: 10.00 currency: USD area: Worldwide time: 14-21 days - type: Tracked Express price: 30.00 currency: USD area: Worldwide tracking: true time: 5-9 days price_min: 1999.99 price_max: 3332.99 currency: USD offers: - name: 90/400mg x 28 pills price: 1999.99 - name: 90/400mg x 56 pills price: 3332.99 --- # Buy Generic Harvoni Ledipasvir/Saofosbuvir Pills Online Harvoni contains a fixed-dose combination of Ledipasvir and Sofosbuvir, representing a breakthrough in hepatitis C treatment. This medication works by targeting multiple stages of the hepatitis C virus lifecycle, offering high cure rates with minimal side effects. It's specifically designed for adults with chronic hepatitis C infection, providing a convenient once-daily regimen that has revolutionized treatment outcomes. Our pharmacy offers Harvoni in 90/400mg pill strength, making advanced hepatitis C treatment accessible through our reliable service. ## Pricing and Options | Dosage | Pack Size | Price (USD) | Price Per Pill | Status | | :--- | :--- | :--- | :--- | :--- | | **90/400mg** | 28 pills | **$1999.99** | $71.43 | In Stock | | **90/400mg** | 56 pills | **$3332.99** | $59.52 | In Stock | [Buy Now](https://liabilis.com/order-harvoni-online-en.html) ## Introduction Harvoni is a fixed-dose combination tablet containing the antiviral agents ledipasvir and sofosbuvir. It belongs to the class of direct-acting antiviral (DAA) medications used to treat chronic hepatitis C virus (HCV) infection. Each tablet delivers a single dose of 90 mg ledipasvir and 400 mg sofosbuvir. While the brand name Harvoni is widely known, the data provided classifies it as a generic product, meaning it is intended to be a therapeutically equivalent alternative to the branded formulation. The medication is administered orally as a single pill once daily. --- ## Quick Reference Facts ``` **Active Ingredient** : Ledipasvir / Sofosbuvir **Form** : Pill 90/400 mg **Primary Uses** : Treatment of chronic hepatitis C virus infection (genotype 1, 4, 5, 6) ``` --- ## What is Harvoni? Harvoni is a tablet that combines two direct-acting antivirals-ledipasvir, an NS5A inhibitor, and sofosbuvir, an NS5B polymerase inhibitor. It is classified as a hepatitis C antiviral regimen. The combination was originally developed by Gilead Sciences and received regulatory approval in 2014. According to the input data, Harvoni is presented as a generic medication; consequently, it is the generic equivalent of the branded Harvoni tablet. Generic versions are required to demonstrate bioequivalence to the reference product, and they are typically marketed under the same active-ingredient name while offering lower costs. Common brand equivalents include the original Harvoni tablets and any other manufacturers’ branded ledipasvir/sofosbuvir products. --- ## How Harvoni Works Ledipasvir and sofosbuvir target different stages of the HCV replication cycle. Sofosbuvir is a nucleotide analogue that is incorporated into the viral RNA chain by the NS5B RNA-dependent RNA polymerase, causing premature chain termination. Ledipasvir binds to the NS5A protein, a multifunctional phosphoprotein involved in viral replication and assembly, thereby disrupting the formation of the replication complex. By blocking both polymerase activity and the replication complex, the combination achieves a synergistic antiviral effect, leading to rapid decline of viral load. The drugs are taken orally, reach peak plasma concentrations within 4-6 hours, and are primarily cleared by the liver and kidneys. The regimen’s high barrier to resistance and short treatment duration (typically 8-12 weeks) underpin its clinical success. --- ## Conditions Treated with Harvoni - **Chronic Hepatitis C Genotype 1 Infection** Ledipasvir/sofosbuvir provides a cure rate >95 % in genotype 1 patients, the most common HCV genotype worldwide. The dual mechanism suppresses viral replication, allowing the immune system to clear infected cells. - **Chronic Hepatitis C Genotype 4, 5, 6 Infections** Clinical trials have shown comparable sustained virologic response (SVR) rates in these genotypes, making Harvoni a pan-genotypic option for many patients. - **Compensated Cirrhosis Due to HCV** In patients with liver fibrosis stage F3-F4, Harvoni remains effective and is often preferred because it does not require interferon and has a favorable safety profile. - **HCV Infection in Patients Co-infected with HIV** Studies indicate that Harvoni achieves SVR rates similar to HCV-mono-infected patients, without significant drug-drug interactions with common antiretroviral regimens. --- ## Is Harvoni the Right Medication for You? Harvoni is most appropriate for adult patients with chronic HCV infection who have been genotyped as 1, 4, 5, or 6 and who have not received prior DAA therapy (or who meet specific retreatment criteria). It is especially recommended for individuals seeking an interferon-free, once-daily regimen with a short treatment duration. Patients with decompensated cirrhosis (Child-Pugh B or C) or severe renal impairment (eGFR < 30 mL/min) require alternative regimens, as Harvoni is not indicated for these populations. Additionally, those with known hypersensitivity to ledipasvir, sofosbuvir, or any tablet excipients should avoid the medication. Pregnant or breastfeeding women should discuss risks with a healthcare professional, as safety data are limited. Overall, suitability should be confirmed by a qualified provider who can assess genotype, liver disease stage, renal function, and potential drug interactions. --- ## Buying Harvoni from [our online pharmacy](https://liabilis.com/order-harvoni-online-en.html) ### Why Choose Our Service? Accessing Harvoni can be challenging due to insurance restrictions or high out-of-pocket costs. [our online pharmacy](https://liabilis.com/order-harvoni-online-en.html) provides a reliable avenue for patients who need a cost-effective, high-quality antiviral option. ### Quality & Safety Assurance We partner with licensed international pharmacies to ensure quality and authenticity. Every shipment undergoes verification against regulatory standards, and the product is stored under controlled conditions to preserve potency. ### Pricing & Access Because Harvoni is presented here as a generic equivalent, the price is substantially lower than the branded version, often approaching the manufacturer’s wholesale cost. This makes a curative HCV therapy attainable for patients facing financial barriers. ### Discreet Delivery Orders are packaged in unmarked, tamper-evident containers and dispatched via express courier with typical delivery within 7 days, or standard airmail in approximately 3 weeks. Privacy is maintained throughout the fulfillment process, ensuring that your medication arrives securely and anonymously. Through our pharmacy service, patients can obtain the medication they need without compromising on safety, affordability, or confidentiality. --- ## Use: Dosing, Missed Dose, Overdose - **Standard Dosing** - Adults: One tablet (90 mg ledipasvir / 400 mg sofosbuvir) taken orally once daily with or without food. Treatment length is usually 8 weeks for genotype 1 patients without cirrhosis, and 12 weeks for those with compensated cirrhosis or other genotypes. - **Missed Dose** - If you realize a dose was missed within 12 hours, take it as soon as you remember and continue with the next scheduled dose. Do not double-dose to compensate. - **Overdose** - In the event of an overdose, seek medical attention promptly. Symptoms may include nausea, vomiting, or abdominal discomfort, but severe toxicity is rare. Contact your local poison control center and provide the exact amount taken. - **Precautions** - Avoid concurrent use of strong inducers of CYP3A4 (e.g., rifampin, carbamazepine) as they may reduce Harvoni exposure. Alcohol consumption does not directly affect the medication but excessive intake can worsen liver disease. Do not operate heavy machinery if you experience dizziness or fatigue. --- ## Safety Information ### ⚠️ Who Should Not Take Harvoni - Patients with known hypersensitivity to ledipasvir, sofosbuvir, or any tablet excipients. - Individuals with decompensated cirrhosis (Child-Pugh B or C). - Severe renal impairment (eGFR < 30 mL/min) unless specifically prescribed by a specialist. ### Common Side Effects - **Fatigue** (occurs in ~30 % of patients) - usually mild and transient. - **Headache** (≈20 %) - can be managed with acetaminophen. - **Nausea** and **diarrhea** (≈10-15 %) - stay hydrated and consider eating smaller, frequent meals. ### Serious Side Effects (Seek Immediate Medical Help) - **Severe rash or Stevens-Johnson syndrome** - discontinue and seek emergency care. - **Hepatic decompensation** (jaundice, ascites, encephalopathy) - rare but requires urgent evaluation. - **Lactate acidosis** (extremely rare) - presents with rapid breathing, abdominal pain, and confusion. ### Drug & Food Interactions - **Amiodarone** - co-administration can cause symptomatic bradycardia; monitor heart rate. - **St. John’s Wort** - induces CYP3A4, reducing ledipasvir levels; avoid. - **Antacids containing aluminum or magnesium** - may decrease absorption of ledipasvir; separate dosing by at least 4 hours. - **Antiretrovirals** (e.g., efavirenz) - may lower sofosbuvir concentrations; review regimen with a clinician. --- ## Off-Label and Investigational Uses of Harvoni - **Pre-exposure prophylaxis for HCV** - Small pilot studies have explored using ledipasvir/sofosbuvir to prevent infection in high-risk populations; efficacy remains investigational. - **Treatment of acute HCV infection** - While officially approved for chronic infection, clinical reports suggest early-stage treatment can achieve rapid viral clearance, though guidelines recommend conventional regimens. - **Use in post-liver-transplant patients** - Some transplant centers employ Harvoni to prevent reinfection of the graft; data support high SVR rates, but formal approval for this indication is pending. All off-label applications should only be pursued under direct supervision of a qualified healthcare provider, given the lack of regulatory endorsement. --- ## Storage & Handling - Store tablets at 20-25 °C (68-77 °F); excursions permitted between 15-30 °C (59-86 °F). - Keep the container tightly closed and protect from moisture and direct sunlight. - Do not use tablets beyond the expiration date printed on the packaging. - Dispose of unused medication according to local hazardous waste guidelines or return to a pharmacy-take-back program. --- ## Frequently Asked Questions **Practical Use & Lifestyle** - **Can I travel internationally with Harvoni tablets?** Yes. Carry the medication in its original container with a copy of the prescription label. Check the destination country’s import regulations for personal quantities of antiviral drugs. - **Will taking Harvoni affect my ability to drive or operate machinery?** Most patients do not experience impairment. If you develop dizziness, fatigue, or visual disturbances, avoid operating vehicles until symptoms resolve. - **Is it safe to drink alcohol while on Harvoni?** Moderate alcohol intake is not contraindicated, but excessive consumption can worsen liver disease and should be avoided. Discuss your drinking habits with your provider. **Product & Formulation Details** - **What do Harvoni tablets look like?** The tablet is oval, film-coated, and typically white to off-white in color, embossed with “90/400” on one side. Appearance may vary slightly between generic manufacturers. - **Can the tablet be split or crushed?** No. The medication should be swallowed whole; splitting or crushing can alter the release characteristics and reduce efficacy. **Regulatory & Safety Nuances** - **Will Harvoni show up on a standard drug test?** Standard employment drug screens do not test for antiviral agents like ledipasvir or sofosbuvir, so it will not be detected. - **Is Harvoni approved for use in patients under 18?** The approved indication is for adults; pediatric use is limited to specific clinical trial settings and requires specialist oversight. - **Are there any restrictions for athletes using Harvoni?** Harvoni is not listed on the World Anti-Doping Agency (WADA) prohibited list, but athletes should disclose all medications to their governing bodies. **Scientific & Clinical Curiosity** - **What were the pivotal trials that led to Harvoni’s approval?** The ION-1, ION-2, and ION-3 phase III trials demonstrated SVR rates of 94-99 % in genotype 1 patients, forming the basis for FDA approval. - **How does Harvoni compare with older interferon-based regimens?** Interferon plus ribavirin required 24-48 weeks, had lower cure rates (50-70 %) and significant side effects. Harvoni’s 8-12 week, interferon-free regimen offers higher efficacy and a markedly better safety profile. --- ## Glossary **Direct-Acting Antiviral (DAA)** : A class of medications that target specific non-structural proteins of hepatitis C virus, thereby inhibiting viral replication. **Sustained Virologic Response (SVR)** : The absence of detectable HCV RNA in blood 12 weeks after completing therapy, considered a cure. **Bioequivalence** : Demonstration that a generic product delivers the same amount of active ingredient to the bloodstream as the reference branded product, within an accepted range. --- ## Disclaimer The information presented about Harvoni is intended for general educational purposes and does not replace professional medical consultation. Treatment decisions, including those concerning off-label applications, should be made under the supervision of a qualified healthcare provider. Readers are presumed to be responsible adults capable of making informed health choices. [our online pharmacy](https://liabilis.com/order-harvoni-online-en.html) provides a channel for obtaining Harvoni to individuals who may encounter limited availability, insurance barriers, or cost concerns, offering a verified and affordable alternative. Always discuss with your physician before initiating, modifying, or discontinuing any medication.